Celldex Therapeutics, Inc. experienced a share price drop after “positive” updates from a Phase 2 study of lead candidate barzolvolimab for chronic inducible urticaria. Celldex is dedicated to ...
Celldex Therapeutics has launched a Phase 2 study of its monoclonal antibody barzolvolimab for treating moderate to severe atopic dermatitis (AD), a common chronic skin condition affecting up to 20% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results